11505 RESULTS
COMMENT The study by DeKosky does not allow for conclusions about whether or not the cholinergic deficit is present at early stages of AD. The data show that there are differences in ChAT activity between a "no cognitive impairment" (NCI) group and a &q
COMMENT In this prospective study, Seshadri et al. measured plasma homocysteine levels in normal elderly individuals and then followed the same individuals for eight years and reassessed their clinical status as well as homocysteine levels. They found that plasma
COMMENT This study shows very similar results to what we reported at the last Neuroscience meeting in San Diego. We found that secreted-type AβPP dose-dependently increased glial differentiation of normal human neural stem cells, and that transfection of the wild
COMMENT Data obtained in the recent prospective epidemiological studies of Wolf et al. and in our studies of a mouse model of Alzheimer's disease (AD) provide a strong case for folic acid supplementation as a preventative approach for AD. The study of the Fr
COMMENT One problem in the Bahn et al. paper is that it lacks confirmation that these changes occur with real Down's syndrome cells, like primary neurons or astrocytes in culture, or in the Down's brain. When they looked at the expression of the AβPP ge
COMMENT The Alzheimer's Society in the UK welcomes all new advances in the treatment of Alzheimer's disease. Memantine is a drug that has been used for many years in Germany, and will now shortly have a Europe-wide license. Memantine works by blocking t
COMMENT I think this is a good paper, and it adds to our transgenic toolbelt. It may, for example, allow us to turn pathology and off, to see if lesions such as plaques can be resolved once the source (e.g., elevated Aβ from an AβPP or PS1 transgene) is removed.
COMMENT This is indeed the first report that newborn neurons in adult brain have morphological and electrophysiological characteristics of adult granule cells, and thereby demonstrates that these new neurons are functional. This represents a major advance by prov
COMMENT Ruth Itzhaki, Matthew Wozniak, Curtis Dobson, University of Manchester, UK. Inflammatory Consequences: Benevolent or Virulent? The main point by Pasinetti et al. is that there is an intriguing paradox: prevention of inflammation appears to be beneficial i
COMMENT I think this is a clever approach to producing a vaccine that would seem more cost-effective than the present Elan vaccine. While the authors claim that their vaccine is highly antigenic, it is hard to know how it would compare to the Elan vaccine without
COMMENT The Role of NSAIDs and Cyclooxygenase on Beta-amyloidosis and Clinical Dementia Several recent developments in the study of anti-inflammatory drugs as possible therapeutic agents to prevent or treat AD must be reconciled: 1. Epidemiologic evidence continu
COMMENT This is one of few studies that have longitudinally explored the relation between lifestyle and dementia. The authors carefully tested the hypothesis that engagement in cognitive activities is associated with both reduced risk for development of dementia
COMMENT Authors' reply: In our study of IDE, we detected five SNPs in IDE occurring at >5 percent frequency, which we tested for association in a minimum sample of over 200 AD cases and 200 controls. Where there was a suggestion of a significant result fo
COMMENT The release from Elan certainly raises more questions for me than it answers. For example, what is the "marker of CNS inflammation" it is referring to? Our first experiments in mice anticipated exactly the outcome that the Aß vaccine would provo
COMMENT Vaccine Disrupting "Scab"? Aβ as a Vascular Sealant That Protects Against Hemorrhage The question whether removing amyloid-β from the brain is therapeutic has been raised again by the recent interruption of the Elan/AHP trial due to clinical sig
